产品
编 号：F753658
分子式：C45H57N7O6
分子量：791.98
分子式：C45H57N7O6
分子量：791.98
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
结构图
CAS No: 2546091-70-5
产品详情
生物活性：
SOP1812 (QN-302) is a naphthalene diimide (ND) derivative with anti-tumor activity. SOP1812 binds to quadruplex arrangements (G4s), and down-regulates several cancer gene pathways. SOP1812 shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. SOP1812 can be used for the research of cancer.
体内研究：
SOP1812 (1 mg/kg；每周静脉注射一次或两次，持续 28 天) 在 MIA PaCa-2 异种移植小鼠和 KPC 小鼠中显示出抗肿瘤活性。Animal Model:Female athymic nude mice with MIA PaCa-2 xenografts
Dosage:1 mg/kg
Administration:Intravenous injection; 1 mg/kg once or twice per week; for 28 days
Result:Showed complete tumor regression and no significant tumor regrowth after day 28 on several animals.
Animal Model:KPC mice with PDAC symptoms
Dosage:1 mg/kg
Administration:Intravenous injection; 1 mg/kg once per week; for 3 weeks
Result:Significantly extended survival of KPC mice and showed a better effect than gemcitabine.
体外研究：
SOP1812 (0-50 nM；96 h) 抑制多种癌细胞的增殖。 SOP1812 (0 -800 nM；6-24 h) 对 hTERT G4 和 HuTel21 G4 具有很强的亲和力。 SOP1812 (40 nM；6-24 小时) 影响 Wnt/β-连环蛋白、轴突导向、Hippo、MAPK 和 Rap1 通路。
SOP1812 (QN-302) is a naphthalene diimide (ND) derivative with anti-tumor activity. SOP1812 binds to quadruplex arrangements (G4s), and down-regulates several cancer gene pathways. SOP1812 shows great affinity to hTERT G4 and HuTel21 G4 with KD values of 4.9 and 28.4 nM, respectively. SOP1812 can be used for the research of cancer.
体内研究：
SOP1812 (1 mg/kg；每周静脉注射一次或两次，持续 28 天) 在 MIA PaCa-2 异种移植小鼠和 KPC 小鼠中显示出抗肿瘤活性。Animal Model:Female athymic nude mice with MIA PaCa-2 xenografts
Dosage:1 mg/kg
Administration:Intravenous injection; 1 mg/kg once or twice per week; for 28 days
Result:Showed complete tumor regression and no significant tumor regrowth after day 28 on several animals.
Animal Model:KPC mice with PDAC symptoms
Dosage:1 mg/kg
Administration:Intravenous injection; 1 mg/kg once per week; for 3 weeks
Result:Significantly extended survival of KPC mice and showed a better effect than gemcitabine.
体外研究：
SOP1812 (0-50 nM；96 h) 抑制多种癌细胞的增殖。 SOP1812 (0 -800 nM；6-24 h) 对 hTERT G4 和 HuTel21 G4 具有很强的亲和力。 SOP1812 (40 nM；6-24 小时) 影响 Wnt/β-连环蛋白、轴突导向、Hippo、MAPK 和 Rap1 通路。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备